A phase Ia trial of SOL 784
Latest Information Update: 08 Sep 2021
At a glance
- Drugs SOL 784 (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- 08 Sep 2021 New trial record
- 02 Sep 2021 According to a Sentinel Oncology media release, McQuade Center for Strategic Research and Development, LLC (MSRD) has entered an agreement with Sentinel Oncology. Under the terms of the agreement, MSRD and Sentinel will collaborate to support this study.